| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cosmo Pharmaceuticals N.V (SW: COPN)
COPN Technical Analysis
5
| As on 9th Jun 2023 COPN STOCK Price closed @ 47.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 54.16 & Strong Sell for SHORT-TERM with Stoploss of 59.88 we also expect STOCK to react on Following IMPORTANT LEVELS. |
COPNSTOCK Price
| Open | 46.45 | Change | Price | % |
| High | 47.60 | 1 Day | 0.50 | 1.07 |
| Low | 46.45 | 1 Week | -0.35 | -0.73 |
| Close | 47.30 | 1 Month | -7.40 | -13.53 |
| Volume | 5287 | 1 Year | -19.80 | -29.51 |
| 52 Week High 70.50 | 52 Week Low 42.85 | ||||
SW Switzerland Most Active Stocks
| CSGN | 0.81 | 0.00% |
| CSGN | 0.81 | 0.00% |
| MBTN | 0.58 | 1.75% |
| ABBN | 34.50 | 0.76% |
| ABBN | 34.50 | 0.76% |
| UBSG | 18.20 | -0.27% |
| UBSG | 18.20 | -0.27% |
| NOVN | 90.17 | -0.22% |
| NOVN | 90.17 | -0.22% |
| NESN | 107.16 | 0.15% |
SW Switzerland Top Gainers Stocks
SW Switzerland Top Losers Stocks
| COPN Daily Charts |
COPN Intraday Charts |
Whats New @ Bazaartrend |
COPN Free Analysis |
|
|
COPN Important Levels Intraday
| RESISTANCE | 49.52 |
| RESISTANCE | 48.81 |
| RESISTANCE | 48.37 |
| RESISTANCE | 47.93 |
| SUPPORT | 46.67 |
| SUPPORT | 46.23 |
| SUPPORT | 45.79 |
| SUPPORT | 45.08 |
COPN Forecast May 2024
| 4th UP Forecast | 74.18 |
| 3rd UP Forecast | 65.56 |
| 2nd UP Forecast | 60.23 |
| 1st UP Forecast | 54.9 |
| 1st DOWN Forecast | 39.7 |
| 2nd DOWN Forecast | 34.37 |
| 3rd DOWN Forecast | 29.04 |
| 4th DOWN Forecast | 20.42 |
COPN Weekly Forecast
| 4th UP Forecast | 59.63 |
| 3rd UP Forecast | 55.68 |
| 2nd UP Forecast | 53.23 |
| 1st UP Forecast | 50.79 |
| 1st DOWN Forecast | 43.81 |
| 2nd DOWN Forecast | 41.37 |
| 3rd DOWN Forecast | 38.92 |
| 4th DOWN Forecast | 34.97 |
COPN Forecast2024
| 4th UP Forecast | 103.18 |
| 3rd UP Forecast | 85.26 |
| 2nd UP Forecast | 74.18 |
| 1st UP Forecast | 63.11 |
| 1st DOWN Forecast | 31.5 |
| 2nd DOWN Forecast | 20.42 |
| 3rd DOWN Forecast | 9.34 |
| 4th DOWN Forecast | -8.58 |
Cosmo Pharmaceuticals N.V ( SW Switzerland Symbol : COPN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
COPN Business Profile
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The company offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; Aemcolo, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth, as well as Rifamycin for irritable bowel syndrome with diarrhoea; and Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers, or other gastrointestinal mucosal lesions. It also provides ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for the induction and maintenance of procedural sedation; Qolotag, a medical device that enhances the visualisation of lesions during sigmoidoscopies; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. Address: Riverside II, Dublin, Ireland, 2
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service